NEW ORLEANS, La., April 27, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 8, 2018 to file lead plaintiff applications in a securities class action lawsuit against Foot Locker, Inc. (NYSE:FL), if they purchased the Company’s shares between August 19, 2016 and August 17, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
Get Help
Foot Locker investors should visit us at https://www.claimsfiler.com/cases/view-foot-locker-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Foot Locker and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 18, 2017, the Company revealed negative financial results for the second quarter of fiscal year 2017, including revenue significantly below expectations, attributed in part to lower same-store sales, that many more stores were being closed than previously announced, and that weaker sales were expected for the rest of the fiscal year.
On this news, the price of Foot Locker’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


California Seeks Paramount Divestitures in Warner Bros. Merger
Tesla Raises Cybertruck Prices by $5,000 in US
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets
Trump Buys SpaceX Shares After Record IPO
Nvidia Eyes Perplexity Investment at $30 Billion Valuation
Ampol Profit Surges as Refining Margins Hit Record Highs
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays
SK Hynix Shares Fall as Workers Reject Wage Deal
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Google Expands Gemini Enterprise With AI Tools for Legal Sector 



